Different dosages of atrovastatin calcium treatment on sarcopenia with moderate to severe frailty in elderly patients
Received:December 12, 2018  Revised:January 17, 2019
View Full Text  View/Add Comment  Download reader
DOI:
Key words:statins;frailty;sarcopenia
Author NameAffiliationE-mail
LIQI 江苏省钟山康复医院 1722163348@qq.com 
李丽丽 江苏省钟山康复医院 1722163348@qq.com 
芮小勇 江苏省钟山康复医院 1722163348@qq.com 
吴剑卿 江苏省南京市鼓楼区广州路324号江苏省人民医院 1722163348@qq.com 
RONG Qi-Fei 江苏省钟山康复医院 rongqifei@126.com 
Hits: 29
Download times: 
Abstract:
      Objective: To investigate different dosages of atrovastatin calcium treatment on sarcopenia with moderate to severe frailty in elderly patients in order to provide reasonable evidence for its use in elderly sarcopenia patients. Methods: Ninety-eight elderly patients with moderate to severe frailty who were taking atrovastatin calcium were randomly divided into three groups (i.e., 20 mg group, 10 mg group and withdrawal group). TG, TC, LDL, and HDL in the peripheral blood; grip strength testing; 4.5-meter walking time; and appendicular skeletal muscle mass (ASM) by DXA were measured before and after treatment. Frailty levels were also assessed and categorized before and after treatment. Results: After 24 months of treatment, we observed that the TC level in the 20 mg group was significantly lower than that in the 10 mg group and the withdrawal group (p values were 0.001 and 0.009, respectively); the grip strength of the 20 mg group and 10 mg group were significantly lower than that of the withdrawal group ((p values were 0.000 and 0.000, respectively); the ASMI of the 20 mg group was also significantly lower than that of the withdrawal group (P=0.017). Moreover we found that the frailty level in the 20 mg group was increased significantly by at least one level from the original level (P=0.036). Conclusions: Statins may further exacerbate age-related declines in muscle function and accelerate frailty.
Close